ABIVAX
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer.
ABIVAX
Industry:
Biotechnology
Founded:
2013-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.abivax.com
Total Employee:
11+
Status:
Active
Contact:
+33(0)1 53 83 08 41
Email Addresses:
[email protected]
Total Funding:
96.2 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Benchmark Holdings
Benchmark Holdings, a pioneering bioagtech company.
OliX Pharmaceuticals
OliX is a clinical stage biotechnology company.
CareDx
CareDx is a novel molecular diagnostics company.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Sofinnova Partners
Sofinnova Partners investment in Post-IPO Equity - Abivax
Invus
Invus investment in Post-IPO Equity - Abivax
TCG Crossover
TCG Crossover investment in Post-IPO Equity - Abivax
Truffle Capital
Truffle Capital investment in Post-IPO Equity - Abivax
Deep Track Capital
Deep Track Capital investment in Post-IPO Equity - Abivax
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Post-IPO Equity - Abivax
Kreos Capital
Kreos Capital investment in Post-IPO Debt - Abivax
Sofinnova Partners
Sofinnova Partners investment in Post-IPO Equity - Abivax
Kreos Capital
Kreos Capital investment in Post-IPO Debt - Abivax
Key Employee Changes
| Date | New article |
|---|---|
| 2021-03-01 | Abivax appoints Dr Sophie Biguenet, M.D., as Chief Medical Officer |
Official Site Inspections
http://www.abivax.com Semrush global rank: 3.09 M Semrush visits lastest month: 5.19 K
- Host name: 104.21.59.143
- IP address: 104.21.59.143
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Abivax"
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.See details»
Our Mission - Abivax
Abivax is committed to exploring and applying revolutionary science in a variety of ways to extend its impact and reach more patients in need. Expanding Our Presence for Future Growth. Abivax now has global headquarters in Paris, …See details»
Abivax - Wikipedia
Abivax focuses on the treatment of inflammatory bowel diseases, namely ulcerative colitis (UC) and Crohn’s disease (CD). Its lead drug candidate, obefazimod, is an oral, first-in-class, small molecule that has demonstrated safety and tolerability as well as profound anti-inflammatory activity in preclinical as well as clinical trials in UC. See details»
Company History | Abivax - Le
The initial public offering for Abivax was announced on Euronext Paris on June 26, with gross proceeds of EUR 57.7M; 2016. Obefazimod showed efficacy in a DSS colitis mouse model. …See details»
Board of Directors - Abivax
Founder of Abivax; Managing Partner of Truffle Capital. June Lee, MD FACCP Venture Partner at 5AM Ventures. Kinam Hong, MD, MBA, CFA Partner at the Crossover Fund Sofinnova. Troy …See details»
Abivax Provides Operational and Key Program Update - Nasdaq
Jul 15, 2024 David Zhang named Chief Strategy Officer Cash position allows for runway into Q4 2025 through ABTECT 8- week induction top-line results PARIS, France, July 15, 2024, 10:00 …See details»
Abivax provides business and operational update
Sep 7, 2023 Abivax U.S. office currently planned to open in the Greater Boston Area in Q4 2023. Dual source Contract Manufacturing Organization (CMO) presence to be established in North …See details»
Abivax Company Profile 2024: Stock Performance
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. …See details»
Corporate Presentation - Abivax
In addition, forward-looking statements reflect Abivax’s expectations, plans, or forecasts of future events and views as of the date of this presentation and are qualified in their entirety by …See details»
Abivax | Official Website - Le
Abivax dispose également d’une bibliothèque de composés chimiques renfermant un potentiel encore inexploité. Nous avons lancé un programme de recherche afin d’utiliser le potentiel qu’offre cette bibliothèque. NOTRE PORTEFEUILLE …See details»
Our Pipeline - Abivax
Oct 11, 2022 Product Development Portfolio. Abivax is in the process of transforming into a commercial-stage company through opportunities to potentially harness the novel mechanism …See details»
Abivax SA, ABVX:PAR profile - FT.com - Financial Times
Nov 22, 2024 Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic …See details»
Our Research - Abivax
Abivax will conduct a dose-ranging Phase 2b clinical trial in moderately to severely active Crohn’s disease (known as ENHANCE-CD). The start of patient enrollment is planned for Q3 2024. …See details»
Abivax 2024 Financial Communication Calendar | Abivax
Dec 31, 2023 PARIS, France, January 4, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused …See details»
Abivax publishes financial reports with the French and U.S.
Apr 5, 2024 Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune …See details»
Abivax reports 2023 financial results and operational update
PARIS, France, April 2, 2024, 8:30 a.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing …See details»
Abivax Announces $235.8 Million IPO - Cooley
New York – October 20, 2023 – Cooley advised Abivax, a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to …See details»
Abivax Reports Positive Interim Efficacy and Safety Analysis of …
PARIS, France, October 3, 2024, 8:30 a.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing …See details»
ABVX Stock Price Quote - Morningstar
5 days ago Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the …See details»